Show simple item record

dc.contributor.authorAgustsson, Tomas Thor
dc.contributor.authorBaldvinsdottir, Tinna
dc.contributor.authorJonasson, Jon G
dc.contributor.authorOlafsdottir, Elinborg
dc.contributor.authorSteinthorsdottir, Valgerdur
dc.contributor.authorSigurdsson, Gunnar
dc.contributor.authorThorsson, Arni V
dc.contributor.authorCarroll, Paul V
dc.contributor.authorKorbonits, Márta
dc.contributor.authorBenediktsson, Rafn
dc.date.accessioned2016-01-04T13:12:22Zen
dc.date.available2016-01-04T13:12:22Zen
dc.date.issued2015-11en
dc.date.submitted2015en
dc.identifier.citationThe epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. 2015, 173 (5):655-64 Eur. J. Endocrinol.en
dc.identifier.issn1479-683Xen
dc.identifier.pmid26423473en
dc.identifier.doi10.1530/EJE-15-0189en
dc.identifier.urihttp://hdl.handle.net/2336/592763en
dc.descriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the pageen
dc.description.abstractPituitary adenomas (PA) are among the most common human neoplasms. To describe the epidemiology and assess the disease burden of clinically significant PAs, population-based studies are needed. Iceland has a small well-defined population. The aim of this study is to describe the epidemiology of PAs in Iceland over an expanded period of time.
dc.description.abstractThis is a retrospective observational study, including all PAs diagnosed in Iceland from 1955 to 2012.
dc.description.abstractExtensive clinical information was gathered in a database. Prevalence rates for all PA subtypes were calculated along with standardized incidence rates (SIR). Sex ratios and relationships with adenoma size, age, and symptoms were assessed.
dc.description.abstractWe identified 471 individuals: 190 men and 281 women. Total prevalence in 2012 was 115.57/100, 000, prolactinomas were most prevalent (54.37/100, 000) followed by non-functioning adenomas (NFPAs) (42.32/100 ,000). Throughout the period, NFPAs were most common (43.0%) followed by prolactinomas (39.9%) and 11.3% had acromegaly and 5.7% Cushing's disease. Women are diagnosed younger with smaller adenomas. Total SIR has increased significantly and is now 5.8/100 000 per year.
dc.description.abstractIn this nationwide study spanning six decades, we have confirmed PAs rising prevalence and incidence rates noted in recent studies. We demonstrated higher overall prevalence and incidence rates than ever previously recorded with an increasing predominance of NFPAs, which is not explained by incidental findings alone. There is a relationship with the introduction of imaging modalities, but the vast majority of patients are symptomatic at diagnosis. This underlines the importance of increased awareness, education, and appropriate allocation of resources for this growing group of patients.
dc.language.isoenen
dc.publisherBioscientifical LTD, Euro Houseen
dc.relation.urlhttp://dx.doi.org/ 10.1530/EJE-15-0189en
dc.rightsArchived with thanks to European journal of endocrinology / European Federation of Endocrine Societiesen
dc.subjectKrabbameinen
dc.subject.meshPituitary Neoplasms/epidemiologyen
dc.subject.meshIcelanden
dc.subject.meshQuality of Lifeen
dc.subject.meshAcromegalyen
dc.titleThe epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study.en
dc.typeArticleen
dc.contributor.department1 ] Landspitali Natl Univ Hosp Iceland, Dept Endocrinol & Metab Med, IS-108 Reykjavik, Iceland, [ 2 ] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland [ 3 ] Landspitali Natl Univ Hosp Iceland, Dept Pathol, IS-108 Reykjavik, Iceland [ 4 ] Icelandic Canc Registry, IS-105 Reykjavik, Iceland [ 5 ] deCODE Genet, IS-101 Reykjavik, Iceland [ 6 ] Landspitali Natl Univ Hosp Iceland, Dept Paediat, IS-101 Reykjavik, Iceland [ 7 ] Guys & St Thomas NHS Fdn Trust, Dept Endocrinol & Diabet, London SE1 7EH, England [ 8 ] Queen Mary Univ London, Barts & London Sch Med, William Harvey Res Inst, Endocrinol, London EC1M 6BQ, Englanden
dc.identifier.journalEuropean journal of endocrinology / European Federation of Endocrine Societiesen
dc.rights.accessClosed - Lokaðen
html.description.abstractPituitary adenomas (PA) are among the most common human neoplasms. To describe the epidemiology and assess the disease burden of clinically significant PAs, population-based studies are needed. Iceland has a small well-defined population. The aim of this study is to describe the epidemiology of PAs in Iceland over an expanded period of time.
html.description.abstractThis is a retrospective observational study, including all PAs diagnosed in Iceland from 1955 to 2012.
html.description.abstractExtensive clinical information was gathered in a database. Prevalence rates for all PA subtypes were calculated along with standardized incidence rates (SIR). Sex ratios and relationships with adenoma size, age, and symptoms were assessed.
html.description.abstractWe identified 471 individuals: 190 men and 281 women. Total prevalence in 2012 was 115.57/100, 000, prolactinomas were most prevalent (54.37/100, 000) followed by non-functioning adenomas (NFPAs) (42.32/100 ,000). Throughout the period, NFPAs were most common (43.0%) followed by prolactinomas (39.9%) and 11.3% had acromegaly and 5.7% Cushing's disease. Women are diagnosed younger with smaller adenomas. Total SIR has increased significantly and is now 5.8/100 000 per year.
html.description.abstractIn this nationwide study spanning six decades, we have confirmed PAs rising prevalence and incidence rates noted in recent studies. We demonstrated higher overall prevalence and incidence rates than ever previously recorded with an increasing predominance of NFPAs, which is not explained by incidental findings alone. There is a relationship with the introduction of imaging modalities, but the vast majority of patients are symptomatic at diagnosis. This underlines the importance of increased awareness, education, and appropriate allocation of resources for this growing group of patients.


This item appears in the following Collection(s)

Show simple item record